Also known as · Terlivaz
Terlipressin
Vasopressin analog for hepatorenal syndrome.
What it is
Terlipressin (Terlivaz) is a vasopressin analog FDA-approved in 2022 for hepatorenal syndrome type 1 in adults. It has long been available outside the US for hepatorenal syndrome and certain other vasodilatory conditions.
Mechanism of action
Vasopressin receptor agonist with effects on splanchnic vasoconstriction. In hepatorenal syndrome, the splanchnic vasoconstriction reduces splanchnic vasodilation and improves renal perfusion.
Approved indications
Hepatorenal syndrome type 1 in adults.
Why this is out of scope at The Tide
Hospital medication for severe hepatorenal syndrome. Requires hospital administration with intensive monitoring. Not appropriate for outpatient peptide clinic.
Where to learn more
Hepatology or critical care medicine.
Related peptides